Podcasts about biotech

In this episode of Data in Biotech, Ross Katz sits down with Kyle Smith and Jacob Mayer from Aprecia Pharmaceuticals to explore how 3D printing is transforming pharmaceutical manufacturing. They dive into the unique binder jetting process, in-cavity printing, and how real-time data and automation are enabling agile, scalable, and precise drug production. Discover how Aprecia's approach is changing the game for clinical trials and personalized medicine. What you'll learn in this episode: >> How Aprecia developed the world's first FDA-approved 3D printed drug >> Why binder jetting stands out among 3D printing methods in pharma >> How in-cavity 3D printing enables real-time tablet-level data collection >> The future of closed-loop control and digital twins in drug manufacturing >> Why 3D printing is key to agile, distributed, and personalized pharma production Meet our guests: Kyle Smith is President and COO of Aprecia Pharmaceuticals, leading strategic growth and innovation in GMP-regulated pharma manufacturing. With 12+ years at Aprecia, he brings deep expertise in engineering, operations, and technology transfer. Jacob Mayer is Director of Engineering Innovation at Aprecia Pharmaceuticals. With a decade of experience across automation, additive manufacturing, and life sciences, he leads the advancement of 3D printing technologies and integrated pharma systems. About the host Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with our guests: Sponsor: CorrDyn, a data consultancyConnect with Jacob Mayer on LinkedIn Connect with Kyle Smith on LinkedIn Connect with us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode!Connect with Ross Katz on LinkedIn Sponsored by… This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn.

Politics can feel overwhelming - but how can scientists, founders, and biotech leaders effectively engage with policymakers to protect innovation and improve patient outcomes? In this episode, host Elaine Hamm, PhD, is joined by Srinu Sonti, JD, Principal at Lewis-Burke Associates LLC, for a candid and insightful conversation on science, policy, and advocacy. Drawing on his experience on Capitol Hill, in health policy, and working with academic medical centers and startups, Srinu breaks down how innovation, funding, and regulation intersect - and why it's critical for scientists and biotech leaders to have a voice in the policy process. In this episode, you'll learn: Why policymakers want to hear directly from scientists, founders, and innovators, and how those conversations shape decisions. Practical ways universities, startups, and small teams can engage lawmakers beyond sending emails or reacting to crises. How policy choices around clinical trials, AI, global collaboration, and advanced therapies impact patients and the future of biotech. Tune in to learn how building authentic relationships with policymakers can demystify science, strengthen innovation ecosystems, and help move life-saving technologies from the lab to the people who need them most. Links: Connect with Srinu Sonti, JD, and check out Lewis-Burke Associates LLC. Connect with Elaine Hamm, PhD, and learn about Tulane Medicine Business Development and the School of Medicine. Check out Pew Charitable Trusts. Connect with Ian McLachlan, BIO from the BAYOU producer. Learn more about BIO from the BAYOU - the podcast. Bio from the Bayou is a podcast that explores biotech innovation, business development, and healthcare outcomes in New Orleans & The Gulf South, connecting biotech companies, investors, and key opinion leaders to advance medicine, technology, and startup opportunities in the region.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a compelling array of advancements and strategic shifts that are shaping the healthcare landscape across the globe.In recent times, the pharmaceutical and biotech sectors have showcased remarkable resilience and innovation, driving forward with significant scientific breakthroughs and clinical trial results. A standout achievement comes from Novo Nordisk, whose recent Phase 2 trial results for its triple agonist targeting obesity reported a remarkable weight loss of up to 19.7% in patients over 24 weeks. This promising development positions Novo Nordisk as a formidable contender in the obesity treatment market, potentially affecting giants like Eli Lilly. With obesity being a significant global health challenge, these findings underscore the potential of multi-targeted approaches in managing this complex condition.Regulatory landscapes continue to evolve, with pivotal approvals marking milestones for therapies targeting rare diseases. Immedica Pharma's Loargys received FDA approval for treating hyperargininemia associated with arginase 1 deficiency, highlighting perseverance in overcoming regulatory hurdles after a prior rejection. Additionally, Sanofi and Regeneron's Dupixent achieved its ninth FDA approval, underscoring its versatile potential across multiple indications. These approvals not only reflect regulatory progress but also emphasize the critical role of persistence in drug development.Ethical considerations remain at the forefront of industry discussions, particularly highlighted by Novartis' settlement in a lawsuit concerning the use of Henrietta Lacks' cells without consent. This resolution underscores ongoing ethical challenges within biomedical research, emphasizing the need for ethical vigilance as companies increasingly rely on human-derived materials.Significant business trends are shaping strategic directions within the industry. Pfizer's acquisition of marketing rights for Sciwind's GLP-1 receptor agonist in China exemplifies a calculated move to dominate the obesity treatment market. This strategic acquisition allows Pfizer to leverage China's vast market potential for type 2 diabetes medications and positions it favorably for future weight loss treatments.On the manufacturing front, AbbVie has made substantial investments in U.S. infrastructure, committing $380 million to new North Chicago API plants as part of a decade-long strategy to inject $100 billion into U.S. operations. This initiative highlights a commitment to bolstering domestic production capabilities amidst global supply chain uncertainties.The complexities of drug development are further illustrated by Roche's decision to halt the development of Enspryng for Duchenne muscular dystrophy due to unsatisfactory progress. This shift in focus reflects the inherent challenges of drug repurposing and the necessity of robust clinical evidence to support new indications.Geopolitical factors also play a significant role in shaping industry dynamics, with recent U.S. Supreme Court decisions impacting international trade agreements. Such geopolitical influences can significantly affect pharmaceutical companies' operations and strategic planning.The collaboration between Astellas and Vir Biotechnology reflects another significant trend in strategic partnerships within the industry. Their $1.7 billion deal centered on a novel bispecific T-cell engager for prostate cancer underscores the growing importance of immuno-oncology and innovative approaches to targeting hard-to-treat cancers.The regulatory front continues to see transformative changes with the FDA unveiling draft guidance for a new approval pathway tailored for bespoke gene-editing therapies. This initiative could expedite personalized genetic treatments and transform patSupport the show

Biotech company Imugene reported its half-year results yesterday. It’s still loss-making, but sharply cutting costs and seeing what appear to be genuinely encouraging clinical results.Its lead cancer therapy, azer-cel, is showing strong response rates in difficult lymphoma cases, with some patients cancer-free for nearly two years - and the FDA has given positive feedback on the company’s strategy.But at the same time, the company’s share price is down around 80pc over the last year.Sean Aylmer speaks to Leslie Chong, CEO and Managing Director of Imugene, about what it takes to run a long-cycle biotech business, trying to develop life-changing treatments while keeping investors engaged.Find out more: https://fearandgreed.com.au/See omnystudio.com/listener for privacy information.

Jenny Opalinski has spent more than a decade inside hospitals where people lose the ability to speak, breathe, swallow, and sometimes survive. A medical speech language pathologist by training, she worked in ICU, neuro rehab, and long term acute care settings, including a Level 1 trauma center, where she watched clinicians absorb 10 to 15 traumatic events in a single shift and then get told to move the crash cart faster next time.That lived reality pushed her to co found The Wellness Shift, an advocacy and education platform focused on healthcare worker burnout, suicide, and assault. In this conversation, Opalinski walks through the moment that changed everything for her: standing in a hospital hallway listening to a family wail after a failed code, followed by a debrief that addressed logistics and ignored grief entirely.She also explains how that work led to Humanity Rx, her podcast about the human cost of medicine, and Dragon's Breath: Calming Tricks for Big Feelings, a children's book that translates evidence based breathing and regulation strategies into language kids can actually use. The episode covers moral injury, time scarcity, false wellness, respiratory muscle training, and why empathy keeps getting treated as an optional expense instead of clinical infrastructure.RELATED LINKSJenny Opalinski on LinkedInThe Wellness ShiftHumanity RxDragon's Breath: Calming Tricks for Big FeelingsAspire Respiratory ProductsFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world.Today, we delve into the latest from an industry that continues to break new ground in both scientific innovation and regulatory landscapes. The pharmaceutical and biotech sectors are buzzing with activity as companies engage in bold strategies and face significant challenges in their quest for groundbreaking treatments.A recent event illustrating the high-stakes nature of this industry involves Novo Nordisk and its decision to conduct a head-to-head clinical trial for Cagrisema against Eli Lilly's Zepbound. This trial, which typically occurs post-approval, was conducted at the candidate stage. Novo Nordisk aimed to establish market dominance by proving superiority early on. However, the trial did not go as planned, with Cagrisema failing to outperform Zepbound. This outcome serves as a reminder of the competitive dynamics in early-stage testing and the strategic risks companies are willing to take in their bid for market leadership.Meanwhile, Gilead Sciences has made a bold move with a $7.8 billion investment in Arcellx, focusing on CAR T-cell therapy. This investment highlights Gilead's commitment to advanced cancer treatments, particularly Anito-cel for relapsed or refractory multiple myeloma. CAR T-cell therapies involve modifying a patient's T-cells to target cancer cells more effectively, representing a significant leap forward in oncological treatments. With an FDA decision anticipated by December 2026, Gilead's investment underscores its strategic focus on transformative therapies that could redefine cancer care.In legal news, Regenxbio has secured a notable victory against Sarepta Therapeutics regarding adeno-associated virus (AAV) technology patents. The appeals court ruling in favor of Regenxbio emphasizes the intricate nature of patent law in biotechnology, where innovations often intersect with naturally occurring biological processes. This decision not only solidifies Regenxbio's intellectual property but also sets a precedent for future patent disputes within the sector.On the regulatory front, Vanda Pharmaceuticals has rebounded from previous setbacks by securing FDA approval for drugs targeting bipolar disorder and schizophrenia. This achievement marks a promising shift for Vanda, demonstrating resilience and adaptability in redirecting focus towards neuropsychiatric conditions. The approval expands therapeutic options for these complex disorders, addressing long-standing unmet needs within mental health care.Despite these advancements, some areas continue to face hurdles. Gene therapies like Casgevy and Lyfgenia for sickle cell disease have struggled to gain traction two years post-launch. These therapies promise a one-time cure by correcting genetic defects but have encountered challenges in achieving widespread adoption. The difficulties reflect broader issues in transitioning from clinical success to market viability.Moreover, workforce reductions at major companies such as Bristol-Myers Squibb and Catalent signal structural changes within the industry. These layoffs may indicate shifts in strategic focus or responses to evolving market pressures as companies strive for efficiency and innovation.Regulatory practices are also undergoing scrutiny as the FDA considers defaulting to single clinical trial requirements for drug approvals. While this move could streamline development processes, it raises concerns about maintaining rigorous safety standards—a balance that remains crucial as companies push to bring innovative treatments to market swiftly yet safely.The dynamic nature of this industry is further highlighted by Candel Therapeutics' recent $100 million royalty deal aimed at launching its prostate cancer treatment. This strategic move underscores growing interest in innovative oncology solutions thaSupport the show

Plus: Renault to take full control of Flexis electric-van. And Nvidia chips for laptop computers set to hit the market this year. Julie Chang hosts. Learn more about your ad choices. Visit megaphone.fm/adchoices

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech we speak with Monika Sumra, Ph.D., about how leadership, culture, and performance emerge from the environment and conditions inside an organization. Dr. Sumra, Founder and Managing Partner at Bunka, Inc., a management consulting firm and advisor to manufacturing-based organizations globally, explains how anthropology, CPIs, and rapid ethnography make culture measurable and operations faster, safer, and more reliable. Deploying a unique lens built on biosocial anthropology, she offers guidance on creating environments for sustainable performance in the complex life sciences industry. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

In this episode of the Crazy Wisdom Podcast, host Stewart Alsop sits down with Jake Hamilton, founder of Groundwire and Nockbox, to explore zero-knowledge proofs, Bitcoin identity systems, and the intersection of privacy-preserving cryptography with AI and blockchain technology. They discuss how ZK proofs could offer an alternative to invasive identity verification systems being rolled out by governments worldwide, the potential for continual learning AI models to shift the balance between centralized and open-source development, and why building secure, auditable computing infrastructure on platforms like Urbit matters more than ever as we face an explosion of AI agents and automated systems. Jake also explains Nockchain's approach to creating a global repository of cryptographically verified facts that can power trustless programmable systems, and how these technologies might converge to solve problems around supply chain security, personal data sovereignty, and resistance to censorship.Timestamps00:00 Introduction to Groundwire and Knockbox02:48 Understanding Zero-Knowledge Proofs06:04 Government Adoption of ZK Proofs08:55 The Future of Identity Verification11:52 AI and ZK Proofs: A New Era14:54 The Role of Urbit in Technology18:03 The Impact of COVID on Trust20:51 The Evolution of AI and Data Privacy23:47 The Future of AI Models26:54 The Need for Local AI Solutions29:51 Interoperability of Knockchain and BitcoinKey Insights1. Zero-Knowledge Proofs Enable Privacy-Preserving Verification: Jake explains that ZK proofs allow you to prove computational outcomes without revealing the underlying data. For example, you could prove you're over 18 without exposing your full identity or driver's license information. The proof demonstrates that a specific program ran through certain steps and reached a particular conclusion, and validating this proof is fast and compact. This technology has profound implications for age verification, identity systems, and protecting privacy while maintaining necessary compliance, potentially offering a middle path between surveillance states and complete anonymity.2. Government Adoption of Privacy Technology Remains Uncertain: There are three competing motivations driving government identity verification systems: genuine surveillance desires, bureaucratic efficiency seeking, and legitimate child protection concerns. Jake believes these groups can be separated, with some officials potentially supporting ZK-based solutions if positioned correctly. He notes the EU is exploring ZK identity verification, and UK officials have shown interest. The key is framing privacy-preserving technology as protection against "the swamp" rather than just abstract privacy benefits, which could resonate with certain political constituencies.3. The COVID Era Destroyed Institutional Trust at Unprecedented Scale: The conversation identifies COVID as potentially the largest institutional trust-burning event in human history, with numerous institutions simultaneously losing credibility with large portions of the population. This represents a dramatic shift from the boomer generation's default trust in authority figures and mainstream media. This collapse is compounded by the incoming AI revolution, creating a perfect storm where established bureaucracies cannot adapt quickly enough to manage rapidly evolving technology, leaving society in fundamentally unmanageable territory.4. Centralized AI Models Create Dangerous Dependencies: Both speakers acknowledge growing dependence on centralized AI services like Claude, with some users spending thousands monthly on tokens. This dependency creates vulnerability to price increases and service disruptions. Jake advocates for local AI deployment using models like DeepSeek R1, running on personal hardware to maintain control and privacy. The shift toward continuous learning models will fundamentally change the AI landscape, making personal data harvesting even more valuable and raising urgent questions about compensation and consent for training data contribution.5. High-Quality Training Data Is Becoming the Primary AI Bottleneck: Stewart argues that AI development is now limited more by high-quality training data than by compute power. The industry has exhausted easily accessible internet data and body-shop-style data labeling. Companies are now using specialized boutique services with techniques like head-mounted cameras for live-streaming world model training. This scarcity is subtly driving price increases across AI services and will fundamentally reshape the economics of AI development, with implications for who controls these increasingly powerful systems.6. Urbit Offers a Foundation for Trustworthy Computing: Jake positions Urbit as essential infrastructure for the AI age because its 30,000-line codebase (versus Unix's three million lines) can be understood by individual humans. Its deterministic, purely functional, and strictly typed design aims for eventual ossification—software that doesn't require constant security patches. This "tiny and diamond perfect" approach addresses the fundamental insecurity of systems requiring monthly vulnerability patches. In an era of AI agents and potential prompt injection attacks, having verifiable, comprehensible computing infrastructure becomes existentially important rather than merely desirable.7. Nockchain Creates a Global Repository of Provable Truth: Jake's vision for Nockchain combines ZK proofs with blockchain technology to create a globally available "truth repository" where verified facts can be programmatically accessed together. This enables smart contracts or programs gated on combinations of proven facts—such as temperature readings from secure devices, supply chain events, and payment confirmations. By using Nock's abstract, simple design optimized for ZK proof generation, the system can validate complex real-world conditions without exposing underlying data, creating infrastructure for coordinating action based on verifiable private information at global scale.

A new federal law is about to require contractors to map their supply chains, vet their vendors, and prove they're not relying on banned biotech companies. Many firms will discover exposure they didn't know they had. We'll explain what's at stake with Alex Major, Partner and Co‑Chair of the Government Contracts & Global Trade Practice at McCarter & English.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

February 13, 2026: AI in Drug DiscoveryIt costs $2.5 billion and up to 10 years of effort to successfully bring a new drug to market.That's an extremely high hurdle to succeed!It's no wonder why the high costs of FDA trials & the elevated rates of failure often result in small-cap drug developers declaring bankruptcy. Biotechnology is one of the stock market's riskiest sectors to invest in.But what if there was a way to change that?What if we could use technology to alleviate some of the biotech industry's deepest and most systemic risks?AI doesn't necessarily produce better drugs. Though it might be able to reduce drug development costs and timelines significantly.And if it did, that would be a game-changer for the entire industry.On today's show, my special guest Manisha Samy and I will discuss how AI-native infrastructure could vastly improve the return profiles of early-stage biotech companies.Our stock of focus will be Recursion Pharmaceuticals (Nasdaq: RXRX) who's creatively using AI to guide several programs in its development pipeline.

This episode is brought to you by B2B Better. We turned down SaaS clients and e-commerce brands to become the only video-first podcast agency for service-based B2B businesses. Specificity is the strategy.  If you've ever said "we can do that" to every client who walks in, this episode is your wake-up call. Host Jason Bradwell breaks down why niching down is the fastest path to becoming the obvious choice, and why being a bit of everything for everyone means you're actually nothing for nobody. Jason's core point is clear: when he set out to build B2B Better, he committed to being specific on two levels - who they serve and what they do. Not just B2B, because B2B is a hemisphere. They went one layer deeper: service-based businesses. Consulting firms, agencies, system integrators, compliance specialists. Companies that sell expertise, not products. People, not software. Trust and relationships, not features and pricing. That's what lends itself to their service: video-first podcasts that turn your point of view into pipeline. Nothing else. The same principle applies to podcasts. When a client says they want to launch a show, Jason's first question is: what's your superpower? Here's the formula. "This is a podcast about X, and unlike other podcasts about X, only we do Y." Most B2B podcasts fail this test. They say "we're a podcast about technology" or "leadership" or "AI." So are thousands of others. There's no "and." There's no reason to choose you. Add the "and" and everything changes. One show in the B2B Better portfolio is Data and Biotech: "a podcast about data science, and unlike other data science podcasts, only we explore it through the lens of biotech manufacturing." Suddenly if you're a data scientist in biotech, there's only one show for you. That specificity drives 75% to 80% episode completion rates, nearly double the industry average because every listener is exactly the right person. The fear of niching down is real. Every founder worries about leaving money on the table. But saying yes to everyone dilutes your positioning, creates operational inefficiency, and kills pricing power. What actually happens when you niche properly: the funnel gets narrower at first, but the people who raise their hand are perfect fits. They convert faster, pay more, stay longer, and refer others in the same niche. Year one it feels limiting. Year three it feels like leverage. Year five it feels like a moat. The framework to choose your niche: look at your best clients, not biggest. Validate the economics. Test your thesis before announcing publicly. Then commit hard and communicate clearly—change the website, the LinkedIn, the pitch deck. Say who you serve and who you don't. Resonance over reach. Always. Chapter Markers 00:00 - The "we can do anything" agency problem 01:00 - Why B2B isn't a niche, it's a hemisphere 02:00 - Choosing service-based businesses as the core niche 03:00 - Selling expertise, not products: why podcasts fit perfectly 04:00 - Video-first podcasts and the full service offering 05:00 - The superpower formula for podcast positioning 06:00 - Data and Biotech: the power of the "and" 07:00 - 75 to 80% completion rates and what resonance looks like 08:00 - Deeply engaged beats loosely interested every time 09:00 - Addressing the fear of leaving money on the table 10:00 - How niching compounds: pricing, referrals, close rates 11:00 - Four-step framework to choose your niche 12:00 - Specialists compound, generalists reset to zero 13:00 - Resonance is a revenue metric, reach is vanity 14:00 - Direct, systematic, results-driven: the B2B Better approach 15:00 - Write your "and" statement this week Useful Links Connect with Jason Bradwell on LinkedIn Listen to Pipe Dream on Podbean Explore B2B Better website and the Pipe Dream podcast 

John Cumbers returns to the Grow Everything podcast for his fourth appearance to discuss the cutting edge of synthetic biology and the upcoming SynBioBeta 2026 conference. From a man who's been bitten by snakes over 200 times to create universal anti-venom, to the race between the US and China in bio-manufacturing, John reveals why the bioeconomy is reaching an inflection point. We explore how AI is transforming organism design, the $50 million deals being struck for AI models in pharma, and why Chinese bio-manufacturing firms are achieving profitability while Western companies struggle. John also shares his vision for cellular reprogramming and longevity, discusses the controversial rollback of US environmental policy, and explains why the "ChatGPT moment" for biology is closer than we think. Plus, learn about stem cell tissue banks that could revolutionize replacement therapy and why SynBioBeta 2030 will actually happen on the moon.Grow Everything brings the bioeconomy to life. Hosts Karl Schmieder and Erum Azeez Khan share stories and interview the leaders and influencers changing the world by growing everything. Biology is the oldest technology. And it can be engineered. What are we growing?Learn more at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.messaginglab.com/groweverything⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Chapters:(00:00:00) - Welcome Back: John Cumbers' Fourth Appearance on Grow Everything(00:01:00) - Death Becomes Her: Longevity on Broadway(00:03:00) - Listening Bars and Ambient Music Experience(00:04:00) - The Peptide Revolution: From Gray Market to Mainstream(00:07:00) - Trump Administration Revokes Clean Air Act: Impact on Biotech(00:12:00) - Biomanufacturing as Economic Development and Climate Solution(00:13:00) - AI, Space, and Solar Energy: Elon Musk at World Economic Forum(00:16:00) - Data Centers in Space: The Future of Energy(00:18:00) - Introducing John Cumbers and SynBioBeta 2026(00:19:00) - The Man Bitten by 200+ Snakes: Universal Anti-Venom Story(00:22:00) - The Schmidt Pain Index and Extreme Science(00:23:00) - History and Evolution of SynBioBeta Over 14 Years(00:25:00) - Bio 500: Big Companies Transforming with Biotech(00:27:00) - Plant-Based Sales Slowdown and Consumer Bio Trends(00:30:00) - Discovery vs. Commercialization: Why 80% of Startups Fail on Execution(00:34:00) - Default Alive Companies: Bootstrapping the Bioeconomy00:36:00) - AI Meets Biology: When's the ChatGPT Moment?(00:39:00) - Sidewinder DNA Assembly: Revolutionary Build Technology(00:42:00) - Design-Build-Test-Learn: Closing the Loop with Self-Driving Labs(00:43:00) - China's Biomanufacturing Dominance: What the West Can Learn(00:49:00) - Free Market Capitalism vs. Centralized Planning(00:52:00) - Should SynBioBeta Take Political Stands?(00:55:00) - Longevity Revolution: Cellular Programming and Stem Cell Banks(00:59:00) - Death Becomes Her and the Market for Living Forever(01:01:00) - AI and Bio: The Singularity is Here(01:03:00) - Human Genome Engineering and the Meta Simulation(01:05:00) - Quick Fire Round: Lantern Bioworks, Moon Conference, and Awards(01:07:00) - Closing: SynBioBeta Discount Code and Final ThoughtsLinks and Resources:Synbiobeta website. Join us! Use code: "Grow Everything" for a discountOneSkinReplacement theory of aging - Jean HebertTopics Covered:synbio, synthetic biology, bioengineering, conferences, networks, biotech, biology, bioliteracy, Bio500, AI and BioHave a question or comment? Message us here:Text or Call (804) 505-5553⁠⁠Instagram⁠⁠ / ⁠⁠Twitter⁠⁠ / ⁠⁠LinkedIn⁠⁠ / ⁠⁠Youtube⁠⁠ / ⁠⁠Grow Everything⁠⁠Music by: Nihilore Production by: Amplafy Media

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of transformative events reshaping the industry landscape, from scientific breakthroughs to regulatory shifts and strategic corporate maneuvers.Let's start with Insmed's Brinsupri, a newly approved respiratory therapy that has captured attention with its projected $1 billion in sales by 2026. This ambitious forecast is grounded in Brinsupri's robust clinical efficacy and the increasing demand for innovative respiratory treatments. This development reflects a broader industry trend where targeted therapies are not only improving patient outcomes but also driving significant revenue growth. As respiratory conditions continue to be a major health challenge globally, the success of therapies like Brinsupri underscores the potential for innovation to meet these critical needs.In parallel, Merck is working strategically with its RSV antibody, Enflonsia, seeking a second-season approval to bolster its competitive stance against Sanofi and AstraZeneca's Beyfortus. The race in infant RSV prevention is intense as companies vie to establish dominance in this crucial segment of infectious disease management. Merck's efforts highlight the broader push within the industry to develop preventive measures that could significantly alter public health landscapes by reducing the incidence of severe respiratory illnesses in vulnerable populations.Meanwhile, regulatory scrutiny remains a constant for pharmaceutical companies. The FDA's recent review of Johnson & Johnson's advertising for Tremfya, targeting ulcerative colitis, emphasizes the agency's commitment to ensuring that efficacy claims are both truthful and transparent. This serves as a reminder of the importance of maintaining regulatory compliance and ethical advertising practices within the industry—a critical aspect as companies navigate complex marketing landscapes while ensuring patient trust.Shifts in leadership within key health organizations are also noteworthy. Jay Bhattacharya stepping into the role of acting CDC chief after Jim O'Neill's departure could signal changes in public health policy and research priorities. Such transitions can have profound effects on how emerging health challenges are addressed, potentially influencing everything from vaccine distribution strategies to research funding allocations.As we turn to policy discussions, President Donald Trump's most favored nation drug pricing proposal continues to stir debate. This initiative aims to lower drug prices by benchmarking them against international rates, but it faces resistance from free-market advocates who argue it could stifle pharmaceutical innovation. The ongoing discussion around drug pricing reform is pivotal, as it impacts both patient access to medications and the incentives for companies to invest in new drug development.Strategic realignments in the contract development and manufacturing organization (CDMO) sector are also making headlines. Recipharm's sale of its Israeli API plant to Scinai Immunotherapeutics, alongside a new CDMO partnership, illustrates how companies are optimizing resources to focus on core competencies and expand service offerings. This strategic shift highlights the dynamic nature of CDMOs as they adapt to changing market demands and technological advancements.In Alzheimer's research, there's promising news with a study suggesting that a blood test could predict when symptoms will appear, representing a significant leap forward in early diagnosis and intervention strategies. These advancements offer hope for altering the treatment landscape of neurodegenerative diseases through timely therapeutic interventions that could improve quality of life for patients. However, challenges remain as seen with Johnson & Johnson pausing enrollment in itsSupport the show

Dans ce numéro du Journal des biotechs, on prend le pouls de l'écosystème biotech en France et en Europe avec Thierry Laugel, managing partner chez Kurma Partners, la société de capital-risque spécialisée dans les sociétés de santé.L'entretien est consacré à Mathieu Charvériat. Le PDG de THX Pharma revient dans le détail sur la grosse annonce récente : l'acord avec Biocodex. Hébergé par Audion. Visitez https://www.audion.fm/fr/privacy-policy pour plus d'informations.

In this episode, she and Niklas explore why drug development takes over a decade, why only ~10% of drugs reach approval, and how clinical trials have become one of the biggest bottlenecks to biomedical progress.They unpack how incentives distort which diseases get treated, why surrogate endpoints matter, and how off-label use, real-world data, and even “bro science” reveal gaps in the current system.They also cover: • Clinical evolution and iterative human testing • Regulatory opacity and open-sourcing FDA filings • Australia's faster Phase 1 model • Human challenge trials and medical freedom • Surrogate endpoints and distorted incentives • Real-world data and off-label discovery • Biotech innovation shifting to China • How better trials unlock biomedical abundanceA conversation for anyone interested in biotech, policy, and the future of drug development. This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit www.infinitacitytimes.com

Superpowers for Good should not be considered investment advice. Seek counsel before making investment decisions. When you purchase an item, launch a campaign or create an investment account after clicking a link here, we may earn a fee. Engage to support our work.Watch the show on television by downloading the e360tv channel app to your Roku, LG or AmazonFireTV. You can also see it on YouTube.Devin: What is your superpower?Gregory: I have the ability to recognize and reframe patterns.Startup failure rates have hovered around 90% for over 30 years. Gregory Shepard, Founder and CEO of Startup Science, decided to tackle this persistent challenge with a comprehensive, science-backed approach. His goal is nothing short of transformative: to reduce failure rates and create a better ecosystem for entrepreneurs.Gregory's research revealed that 47.1% of startups fail within the first 18 months, with the remaining failures often linked to poor decisions made during that critical period. “There's no industry I can think of that would be okay with 90% of the people trying to succeed failing,” he explained. “I decided to do something about it.”Startup Science offers a centralized platform where entrepreneurs, investors, mentors, and support organizations can connect and collaborate. Gregory has worked to eliminate fragmentation in the startup ecosystem by providing tools, resources, and education—all free for founders. This mission is fueled by his belief that entrepreneurship drives innovation and can create opportunities for people from all backgrounds.Gregory's commitment to democratizing entrepreneurship extends to the way he's raising funds for Startup Science. He's launched a regulated crowdfunding campaign on Wefunder, allowing anyone—not just accredited investors—to support his mission. “If somebody invests in Startup Science, you're investing into all of the startups that we're helping, which is 100,000 of them at the moment,” he said.Gregory's passion is deeply personal. Growing up in poverty, he understands the barriers many entrepreneurs face. That empathy drives his vision to create an accessible, equitable platform that empowers founders to succeed while transforming the global economy.By leveraging his scientific approach to analyzing startup success and failure, Gregory is helping entrepreneurs avoid predictable pitfalls and build sustainable businesses. His efforts could fundamentally reshape the entrepreneurial landscape, enabling innovation to thrive.To learn more or support this initiative, visit Startup Science's crowdfunding campaign. This is an opportunity to back a proven entrepreneur who's committed to doing good for the world.tl;dr:Gregory Shepard shares his mission to reduce startup failure rates with his platform, Startup Science.Startup Science connects fragmented startup ecosystem elements, offering free tools and resources for founders.Gregory discusses his scientific research on startup success and his passion for democratizing entrepreneurship.He highlights his Wefunder campaign, inviting anyone to invest in Startup Science and support entrepreneurs.Gregory explains his superpower, pattern recognition, and how it drives his success in building ecosystems.How to Develop Pattern Recognition As a SuperpowerGregory's autistic diagnosis has sharpened his ability to identify and reframe patterns; a skill he calls pattern recognition. “I have the ability to recognize and reframe patterns…startup science is a result of this,” he explained. Gregory sees connections others might overlook, enabling him to create solutions that integrate fragmented systems into cohesive ecosystems. He describes it as understanding how seemingly separate components interact, much like a solar system where the founder is the sun and other elements orbit around them.Gregory's superpower was pivotal in building and selling Affiliate Traction to eBay Enterprise Marketing Solutions. He noticed that affiliate marketing—now a cornerstone of influencer marketing—was fragmented, with disconnected tools and processes. Gregory envisioned a unified system and developed software that brought these elements together. By connecting the dots, he transformed the industry and created a successful company, later replicating this approach with other ventures.Tips for Developing Pattern Recognition:Identify the structure of a system or process by analyzing its components and relationships.Observe how elements interact within a system and look for inefficiencies or gaps.Reimagine connected systems as an ecosystem where all parts work collaboratively.Practice applying this framework in various contexts, from business to social environments.By following Gregory's example and advice, you can make pattern recognition a skill. With practice and effort, you could make it a superpower that enables you to do more good in the world.Remember, however, that research into success suggests that building on your own superpowers is more important than creating new ones or overcoming weaknesses. You do you!Register Now!Guest ProfileGregory Shepard (he/him):Founder and CEO, Startup ScienceAbout Startup Science: Startup Science is the unified platform for the startup ecosystem, built to support founders and the organizations that help them succeed.We serve entrepreneurs, accelerators, universities, government programs, mentors, investors, and service providers in one connected system, so everyone operates with shared structure, shared data, and clearer outcomes.Entrepreneur Support Organizations work with Startup Science to provide modern program management infrastructure to run their cohorts, deliver consistent curriculum, track founder progress, and report measurable impact, without reinventing the process every cycle.Founders gain access to trusted education, tools, and ecosystem support in one place as they work with their advisors, software and service providers, and other key stakeholders to build their companies.Our mission is to bring clarity, coordination, and effectiveness to entrepreneurship at scale. Website: startupscience.ioCompany Facebook Page: facebook.com/bossstartupscienceInstagram Handle: @startupscience.io Other URL: wefunder.com/startupscienceBiographical Information: Gregory Shepard is a visionary entrepreneur and business leader who has built and sold twelve companies across BioTech, TransitTech, AdTech, and MarTech. In 2016, he sold two of his businesses in a landmark $925 million cross-brand deal, earning four private equity awards.In 2024, he published The Startup Lifecycle with Penguin Random House, receiving acclaim from global leaders and institutions. He has contributed over 100 articles to major publications, hosted Startup Science on Forbes Radio, and co-founded the Fulbright Entrepreneurship Initiative.A sought-after speaker, Shepard has delivered keynotes at TEDx, Ivy League universities, and top conferences worldwide. His personal journey—from overcoming dyslexia, neurodivergence, and poverty to becoming a serial entrepreneur—adds depth to his inspiring message.Committed to “altruistic capitalism,” he integrates social and environmental responsibility into business. His journey proves that with passion, resilience, and a willingness to challenge convention, extraordinary success is within reach.LinkedIn Profile: linkedin.com/in/gregshepardInstagram Handle: @gregshepard_ Personal Twitter Handle: @GregShepard_The Super Crowd, Inc., a public benefit corporation, is proud to have been named a finalist in the media category of the impact-focused, global Bold Awards.Support Our SponsorsOur generous sponsors make our work possible, serving impact investors, social entrepreneurs, community builders and diverse founders. Today's advertisers include rHealth, and SuperCrowd26 featuring PurposeBuilt100™️. Learn more about advertising with us here.Max-Impact Members(We're grateful for every one of these community champions who make this work possible.)Brian Christie, Brainsy | Cameron Neil, Lend For Good | Carol Fineagan, Independent Consultant | Hiten Sonpal, RISE Robotics | John Berlet, CORE Tax Deeds, LLC. | Justin Starbird, The Aebli Group | Lory Moore, Lory Moore Law | Mark Grimes, Networked Enterprise Development | Matthew Mead, Hempitecture | Michael Pratt, Qnetic | Mike Green, Envirosult | Nick Degnan, Unlimit Ventures | Dr. Nicole Paulk, Siren Biotechnology | Paul Lovejoy, Stakeholder Enterprise | Pearl Wright, Global Changemaker | Scott Thorpe, Philanthropist | Sharon Samjitsingh, Health Care Originals | Add Your Name HereUpcoming SuperCrowd Event CalendarIf a location is not noted, the events below are virtual.SuperCrowd Impact Member Networking Session: Impact (and, of course, Max-Impact) Members of the SuperCrowd are invited to a private networking session on March 17th at 1:30 PM ET/10:30 AM PT. Mark your calendar. We'll send private emails to Impact Members with registration details. Upgrade to Impact Membership today!Community Event CalendarSuccessful Funding with Karl Dakin, Tuesdays at 10:00 AM ET - Click on Events.If you would like to submit an event for us to share with the 10,000+ changemakers, investors and entrepreneurs who are members of the SuperCrowd, click here.Manage the volume of emails you receive from us by clicking here.We use AI to help us write compelling recaps of each episode. Get full access to Superpowers for Good at www.superpowers4good.com/subscribe

In this episode, Peg Crowley-Nowick speaks with Joseph Elassal, MD, MBA, Chief Medical Officer of Ankyra Therapeutics, about the strategic, operational, and financial realities of leading clinical development from pre-IND through proof of concept and toward commercialization.   Drawing on experience across large pharma, biotech partnerships, and early-phase oncology, Joe shares a practical roadmap for new and aspiring CMOs. They discuss how to prioritize essential capabilities, including clinical operations, regulatory strategy, biostatistics, and pharmacovigilance, while determining the right time to introduce Medical Affairs. The conversation outlines how to scale teams at critical inflection points such as IND clearance, Phase 2 proof of concept, and advancement into Phase 3.   The episode also examines investor and board expectations, CRO selection, capital efficiency, cash runway management, and the performance metrics CMOs are ultimately judged on—from disciplined milestone execution to generating meaningful clinical data. This episode offers actionable insight for biotech founders, clinical development leaders, medical affairs professionals, and emerging CMOs navigating the path from early development to launch.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a wide array of topics, from groundbreaking therapies and strategic corporate moves to regulatory shifts and industry trends shaping the future of healthcare.We begin with Eli Lilly, which is making significant strides with its combined Zepbound and Taltz therapy, showing promising results in the treatment of psoriasis and obesity. This combination therapy, initially successful in psoriatic arthritis, is set to transform treatment protocols by bridging gaps between psoriasis and obesity. This dual-targeting approach highlights a burgeoning trend in the industry: the use of combination therapies to enhance patient outcomes while streamlining treatment regimens. This strategy not only promises better management of interconnected conditions but also reflects a broader industry goal of maximizing therapeutic reach with existing drugs.Novartis is advancing its portfolio with the oral BTK inhibitor, Rhapsido, following a successful Phase 3 trial for a new chronic hives subtype. This development underscores Novartis's commitment to addressing niche markets and unmet medical needs, emphasizing the pharmaceutical industry's focus on expanding the utility of existing drugs. Additionally, Novartis has entered into a notable partnership with Macrocycle Biotech for cardiovascular drug development. This collaboration represents a broader trend where large pharmaceutical companies seek innovative partnerships to expand their therapeutic portfolios through cutting-edge biotech solutions.Meanwhile, Moderna's influenza vaccine submission has been accepted by the FDA after an initial rejection, illustrating a responsive regulatory environment crucial for timely access to vaccines amid potential flu outbreaks.Johnson & Johnson's $1 billion investment plan in the U.S., focusing on cell therapy, aligns with broader industry trends towards personalized medicine and advanced therapeutic approaches. This investment is part of a strategic pivot towards cell and gene therapies that promise to redefine treatment pathways for complex diseases. Similarly, Bayer's $7.25 billion settlement over Roundup litigation shows an industry keen on resolving legal challenges swiftly to refocus efforts on innovation.Regulatory reforms are also gaining attention, with proposals aimed at streamlining FDA processes to enhance drug access and reduce burdens. These reforms could significantly impact drug development timelines and market entry strategies, reflecting an ongoing discourse on balancing regulation with fostering innovation.On a global scale, Stada's €85 million investment in Saudi Arabia points to a strategic move towards enhancing supply chain resilience in the Middle East and North Africa. This aligns with industry trends focusing on regional manufacturing capabilities to ensure drug availability while reducing logistical complexities.A notable example of strategic resource allocation is Eli Lilly's $100 million upfront payment for CSL's IL-6 antibody development rights. This reflects an adaptive approach where initial clinical setbacks are seen as opportunities for new therapeutic ventures rather than dead ends.Turning our attention to Alzheimer's research, Korsana Biosciences has emerged from stealth mode with substantial funding aimed at developing an anti-amyloid antibody capable of crossing the blood-brain barrier. This effort addresses a critical need within Alzheimer's disease treatment—a field marked by intense competition and scientific challenge. Parallelly, IQVIA Biotech highlights the importance of accelerating early-stage interventions for Alzheimer's through data analytics and optimized clinical trials. Such efforts aim to expedite regulatory approvals and bring new therapies to market faster—a trend indicative of leveragSupport the show

Reinventing Retirement: The Future of the 401(k) w/ Ted Benna the Father of the 401k - AZ TRT S07 EP03 (285) 2-22-2026       Things We Learned This Week ·         The 401(k) Was Almost an Accident - A small 1978 tax provision turned into one of the most important financial innovations in modern history. ·         Regulation Built the Framework - The original law was only two pages. The real structure came later through Treasury rules and regulatory oversight. ·         Many Americans Still Aren't Financially Prepared - Nearly half the population lacks meaningful emergency savings — even with access to retirement plans. ·         Incentives Change Behavior - The Radish Plan ties savings to performance metrics, gamifies engagement, and may improve participation and retention. ·         Retirement Isn't Just About Growth — It's About Income - As you approach retirement, risk management and guaranteed income strategies become more important than aggressive growth.   Guests: Ted Benna, Benna 401K http://benna401k.com   Ted Benna, Father of the 401K, has worked in pension and retirement benefits industry for 60 years, and literally wrote the book on the 401K. He was a pioneer in the early 80s in designing the early 401K Plans, and then getting them approved by the IRS to be the model still used today.   Books:  401K Forty Years Later (2018) – history of the 401K 401K & IRA for Dummies Updated Version (2021)     https://radishplan.com/ An incentive-based model designed to help businesses retain top talent, increase profitability, and provide real financial security for employees.       Notes Guest: Ted Benna – Father of the 401(k) Topic: The Past, Present & Future of Retirement Savings Segment One: The Birth of the 401(k) The Accidental Revolution (1978–1980) ·         In 1978, a small two-page provision was added to the IRS tax code. ·         It allowed employees to defer compensation and receive tax advantages. ·         By 1980, Ted Benna helped launch the first 401(k) plan. ·         Designed for private companies (401k). ·         Government employees received the 457. ·         Nonprofits and schools had 403(b). ·         Individuals had IRAs. How It Changed America ·         Employees contribute directly from paychecks. ·         Employers can match contributions. ·         Pre-tax deductions reduce taxable income. ·         Created a culture of saving. ·         Today: Over $15 trillion saved in 401(k) plans. Early Challenges ·         Legal ambiguity at first. ·         Treasury had to create detailed regulations. ·         Oversight from: o    Department of Labor o    Treasury o    SEC ·         Subject to executive orders over the years. ·         New York Times coverage in early 80s accelerated adoption. ·         Ongoing class-action lawsuits and regulatory scrutiny. The Evolution Continues ·         Private equity now entering 401(k) investment menus. ·         Target-date funds continue to evolve. Segment Two: The Radish Plan – A New Model for 401(k)s The Problem Today ·         20–60% of Americans cannot access funds when needed. ·         Nearly 50% have little to no emergency savings. ·         Traditional 401(k)s are complex, costly, and burdened by red tape. ·         Many small businesses avoid offering plans. Introducing the Radish Plan ·         Employer-funded 401(k) model. ·         Incentive-based contributions tied to KPIs. ·         Similar to profit-sharing — not a flat percentage. ·         Rewards employees for hitting performance metrics. Real-World Example ·         Trucking company model: o    Custom incentives o    Performance-based rewards o    Visible progress tracked via mobile app ·         Gamified experience increases engagement. Why "Radish"? ·         The radish is one of the fastest-growing vegetables. ·         Long roots = deep savings foundation. ·         Visible incentives = motivation. Benefits to Employers ·         Helps recruit and retain employees. ·         Reduces turnover. ·         Saves on FICA taxes. ·         Tax credits available to set up plans. ·         Adoption agreement: 2½ pages (vs. traditional 20+ pages). ·         ~$1,500 setup cost. ·         SaaS platform integrates with payroll (Finch aggregation). ·         Lower software costs.

This job market needs a different approach - tune in to hear why. If you've been applying to roles, asking for promotions, taking on stretch work, and getting ghosted or hearing “not yet” or “there's no budget,” this conversation is for you.When budgets tighten and leaders become selective, performance alone isn't enough. In these environments, they don't promote or hire “good enough.” They move toward the person who feels necessary. And when the rules aren't clear, it's easy to internalize stalled growth as a personal failure instead of a strategic gap.So I'm also going to share the insider conversations that happen behind closed doors of leadership meetings.In this episode, you'll learn:Why performance reviews and stretch assignments don't automatically lead to advancementWhat talent conversations actually focus on behind closed doorsHow lack of clarity gets exposed quickly in a tight marketWhy perception and positioning matter as much as credentialsDetails about my book releasing February 24th - Your Worthy Career: A Science-Backed Method to Build a Meaningful Career in Pharma and Biotech.If you've been wondering why it feels harder than it should, this episode will help you see what's really happening—and what to think about differently.Book Waitlist: My book is available February 24th! Your Worthy Career: A Science-Backed Method to Build a Meaningful Career in Pharma and Biotech join the waitlist here. Are you a woman in Pharma/Biotech who wants to improve her career? Learn more and apply to work with me here. Love the podcast? Share your feedback by leaving us a review. Thank you!Connect on SocialsLinkedInInstagram

Where do scientific breakthroughs really begin, and how much space do we leave for curiosity, intuition, and creative thinking along the way? In this episode, host Elaine Hamm, PhD, is joined by Auni Williams, PhD, a postdoctoral scholar at Penn State University, for a thoughtful and refreshing conversation about “night science.” Together, they explore the idea that behind every polished grant, publication, or protocol is a messier, more human process driven by curiosity, imagination, and the freedom to explore unconventional ideas. From historical examples of scientific breakthroughs to personal stories from the lab, this episode invites listeners to rethink how discovery really happens. In this episode, you'll learn: What “night science” is and why embracing early, unpolished ideas is critical for innovation and discovery. How modern research culture can unintentionally suppress creativity – and what institutions and leaders can do to protect exploratory thinking. Why communicating science as a human, curiosity-driven process is essential for engaging both scientists and the public. Tune in to learn how making space for curiosity, creativity, and night science can reignite passion for research and lead to the next generation of scientific breakthroughs. Links: Connect with Auni Williams, PhD, and learn more about Penn State University. Connect with Elaine Hamm, PhD, and learn about Tulane Medicine Business Development and the School of Medicine. Learn more about François Jacob, Barry Marshall, August Kekulé, Operation Everest, American Heart Association Funding, and Cormac McCarthy's essay. Listen to our previous episode with Walter Isaacson. Connect with Ian McLachlan, BIO from the BAYOU producer. Learn more about BIO from the BAYOU - the podcast. Bio from the Bayou is a podcast that explores biotech innovation, business development, and healthcare outcomes in New Orleans & The Gulf South, connecting biotech companies, investors, and key opinion leaders to advance medicine, technology, and startup opportunities in the region.

In this episode of Careers in Discovery, Tyler is joined by Marc Damelin, Chief Scientific Officer at Alphina Therapeutics. Marc shares his journey from physics undergraduate to Biotech leader, and how a love of problem‑solving gradually drew him from yeast genetics into human disease and ultimately into drug development. After a decade in big pharma working on antibody–drug conjugates, he steps into Biotech leadership, first at Mersana and now at Alphina, where he's pioneering a new class of ADCs built around NAMPT inhibition. Along the way, Marc reflects on choosing industry without having a clear plan, understanding what makes a role the right fit, and why being truly data‑driven is one of the most important habits a scientist can develop. An open, forward‑looking conversation about evidence, judgment and the momentum that comes from backing the right ideas at the right time.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of breakthroughs and strategic maneuvers that are reshaping the landscape of this dynamic industry.Roche is making waves with its antibody Gazyva, initially recognized for cancer treatment. The company has successfully ventured into autoimmune diseases, targeting kidney conditions. Recent phase 3 trials have reinforced Gazyva's efficacy in treating immune-mediated kidney diseases, building on its prior approval for lupus nephritis. This marks a potential paradigm shift from oncology to autoimmune therapy applications, offering a promising new avenue for treating complex kidney disorders. Such advancements underscore the power of immune modulation in addressing severe health conditions.Turning to oncology, Eli Lilly is expanding the use of its cancer drug, Retevmo. Originally approved for specific lung and thyroid cancers with rare biomarkers, Lilly is now exploring its use in the adjuvant setting for non-small cell lung cancer. This effort reflects a broader trend in oncology: companies are increasingly looking to extend the application of targeted therapies beyond their initial indications. This expansion could significantly enhance treatment options and improve patient outcomes.In ophthalmology, Ocular Therapeutix is preparing for an FDA filing following positive phase 3 results for its wet age-related macular degeneration treatment. Their candidate, AXPAXLI, showed superior efficacy compared to Regeneron's Eylea in head-to-head trials. Despite investor skepticism, Ocular remains confident in its product's potential to impact retinal disease management positively. The competitive landscape in ophthalmology is fierce, and innovative treatments with substantial clinical benefits over existing therapies can redefine standards of care.Eli Lilly is also strategically stockpiling Orforglipron, its oral GLP-1 candidate, in anticipation of FDA approval for obesity treatment. This proactive measure aims to prevent supply chain issues seen during previous GLP-1 launches. It reflects an industry-wide focus on ensuring product availability at launch to meet growing market demand effectively.On the regulatory front, there are significant shifts as well. The Trump administration's renewed pilot of 340B rebates aims to optimize drug pricing frameworks. Novartis has secured a long-term supply agreement with Niowave for Actinium-225 (Ac-225), crucial for developing targeted cancer therapies. This highlights the sustained demand for radiopharmaceutical isotopes as part of precision medicine initiatives.Biopharma funding is expected to recover steadily by 2026, albeit with a cautious approach favoring de-risked assets over broader platform technologies. Venture capitalists prefer predictable returns amidst an evolving market landscape.Now, let's turn to Japan, where Innovacell is planning a $92 million IPO on the Tokyo Stock Exchange. This move signals a renewed interest in biotech within the region after a long drought in IPOs. Financial strategies like these are vital for advancing cell therapies that hold promise for treating conditions once deemed challenging.Gilead Sciences has acquired synthetic lethal therapy from Genhouse Bio through a $1.5 billion deal, further underscoring the growing interest in synthetic lethality as a novel cancer treatment approach. This strategy focuses on targeting tumors while sparing normal cells, offering more effective therapies with fewer side effects.In mental health innovations, Compass Pathways has reported positive results from its pivotal trial using psilocybin for treatment-resistant depression. The success of this phase 3 trial highlights the potential role of psychedelics in psychiatric care and could revolutionize mental health treatments by providing new options Support the show

Sarah Gromko and Matthew Zachary go back to SUNY Binghamton in the early 1990s, when they were barely 19 and living inside rehearsal rooms. She starred in campus musical theater productions. He served as pianist and music director for many of those shows and played rehearsal piano for the THEA101 repertory company. This episode reunites two former theater nerds who grew up and took very different paths through art, illness, and work that still circles the same truth.Gromko trained as a singer and composer, studied film scoring at Berklee College of Music, worked in New York and New Orleans, then moved into healthcare as a speech language pathologist and recognized vocologist. She explains aphasia, apraxia, dysarthria, and dysphagia with clarity earned from the clinic. She recounts helping a 16 year old gunshot survivor in New Orleans speak again using Melodic Intonation Therapy. The conversation covers voice banking for ALS, gender affirming voice care, and the damage caused when medicine confuses speech loss with intelligence loss. The result feels like an epic reunion powered by 1990s nostalgia and sharpened by decades of lived consequence.RELATED LINKSSarah GromkoGramco VoiceMelodic Intonation TherapyFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This Biotech Stock Is Disrupting Cancer Treatment - Meet Raphi Levy, CFO, Alpha Tau $DRTSGuest Raphi Levy, CFO, Alpha Tau Company Alpha TauTicker: $DRTSWebsite https://www.alphatau.com Raphi's BioRaphi Levy has served as our Chief Financial Officer since 2019. Prior to joining us, Mr. Levy served in the Investment Banking Division at Goldman Sachs from 2006 until 2019 in New York and Tel Aviv, most recently serving as Executive Director in charge of healthcare banking in Israel.Mr. Levy has served as a director of MX Management LP since April 2022. Mr. Levy holds a B.S. in Economics from the Wharton School of Business, University of Pennsylvania, and a B.S.E. and M.S.E. in Electrical Engineering from the School of Engineering and Applied Science, University of Pennsylvania. Company BioAbout Alpha Tau Medical Ltd. Founded in 2016, Alpha Tau is an Israeli oncology therapeutics company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224 impregnated sources. When the radium decays, its short-lived daughters are released from the sources and disperse while emitting high-energy alpha particles with the goal of destroying the tumor. Since the alpha-emitting atoms diffuse only a short distance, Alpha DaRT aims to mainly affect the tumor, and to spare the healthy tissue around it.

When Terry Pirovolakis learned his son had an ultra-rare neurodegenerative disease, SPG50, he refused to accept “no options.” What started as a desperate search for hope became Elpida Therapeutics, a nonprofit driving gene therapy innovation for multiple rare diseases. In this episode, Terry shares the remarkable journey from diagnosis to clinical trials, the power of partnerships, and why urgency matters when every day counts.Show NotesFrom Mystery to Medicine: The Science Behind a Mother's Search | PodcastTaking a Customized and Collaborative Approach to Therapeutic Development | PodcastRare Disease Research for Drug Development | Charles RiverRare Disease | Charles RiverDiscovery | Charles RiverBeyond The Diagnosis

a16z general partner Jorge Conde talks with Vasant Narasimhan, CEO of Novartis International, about transforming a 250-year-old conglomerate into a pure play medicines company and unlocking $180 billion of value in the process. They cover Novartis's platform technologies: cell and gene therapies, RNA medicines, and radioligand therapies. They also discuss AI in drug discovery, the rise of China as a biotech competitor, and what Vasant looks for when evaluating startup partnerships, including his advice on the killer experiments and CMC work that can make or break a deal. Resources: Follow Vasant Narasimhan on X: https://twitter.com/VasNarasimhanFollow Jorge Conde on X: https://x.com/JorgeCondeBio  Stay Updated:Find a16z on YouTube: YouTubeFind a16z on XFind a16z on LinkedInListen to the a16z Show on SpotifyListen to the a16z Show on Apple PodcastsFollow our host: https://twitter.com/eriktorenberg Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Jared Bauer, Cofounder and CEO at Seek Labs, talks about his adventures in company turnarounds, and setting up Seek Labs to improve patient diagnoses and to discover and develop new treatments for infectious diseases. Jared explains the technology convergence that was needed to build Seek Labs' AI diagnostic and CRISPR-based therapeutics platform, an African Swine Fever proof-of-concept study that reduced viremia in pigs, mapping pathogens for rapid target design, and engaging with the FDA and global regulatory agencies.       Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

Welcome to Automating Quality, the life sciences–focused show that bridges the gap between automation and quality management. In this episode, our host Philippe welcomes Paul Michel, Senior Consultant at SkillPad, with over 27 years of experience in the pharmaceutical and biopharmaceutical industries, including more than two decades in manufacturing. Paul specializes in GMP training, compliance readiness, and supporting organizations through the complexities of product development and commercial manufacturing. Together, they explore the realities of GxP compliance in biopharma manufacturing — from the scientific complexity of biologics and evolving regulatory expectations to the growing demand for specialized quality skills and the expanding role of CDMOs. The conversation highlights how automation, digital maturity, and strong quality foundations are becoming essential to sustain growth in this fast-evolving sector.   Key Takeaways 02:11 Why biologics manufacturing is fundamentally more complex than small molecule production 04:10 How living cell systems introduce variability and demand tight process control 05:29 Why scale-up in biomanufacturing is scientifically challenging and risk-prone 10:00 The role of ICH Q5 guidelines and comparability studies in biologics compliance 13:06 The growing demand for advanced quality skills in biologics and digital environments 17:18 How modern CDMOs enable faster development from DNA to IND through platform approaches 20:47 Why automation and digitalization are critical to closing the CDMO capacity gap   Contact Paul Michel on LinkedIn here: Paul Michel (He/Him) | LinkedIn Contact us at solabs-podcast@solabs.com for questions or feedback!

Eric k. Mangiardi, Biotech CEO of Q3 Medical Device Limited, located in Dublin Ireland, shares his unique perspective on health care delivery with innovative biodegradable stents useful in Gastroenterology, Urology and beyond.

Recorded October 31, 2025 In this episode of BioTalk Unzipped, Gregory Austin and Dr. Chad Briscoe sit down with Dr. Kate Neville, immunologist turned seasoned biotech patent attorney at Marshall, Gerstein & Borun, to unpack one of the most misunderstood and mission-critical areas of life sciences: intellectual property.If you are a biotech founder, scientist, executive, or investor, this conversation is essential listening.We explore what patent prosecution really means, when startups should begin thinking about IP protection, how “freedom to operate” can determine commercial viability, and how emerging AI tools are reshaping the patent landscape.Dr. Neville brings 25+ years of experience guiding university spin-outs, biotech startups, and global pharmaceutical companies through complex patent strategy. She has helped secure patents for FDA-approved drugs and offers a rare dual perspective as both scientist and attorney.In This Episode We Discuss:• The difference between patent prosecution and patent litigation• Why it is never too early for biotech startups to think about IP• The U.S. one-year grace period vs. Europe's stricter disclosure rules• What “Freedom to Operate” really means for commercialization• Antibody patents, CDR regions, and the doctrine of equivalents• How premature disclosure can impact global patent strategy• The real-world back-and-forth of patent office “office actions”• AI-assisted prior art search at the USPTO — opportunity or risk?• How funding cycles influence patent filing decisions• Women in biotech leadership and venture funding disparities• The most rewarding part of protecting life-changing therapiesWe also break down the USPTO's new AI pilot programs designed to modernize patent examination and discuss how artificial intelligence may impact biotech patenting over the next several years.Why This MattersIntellectual property is often the single most valuable asset in a biotech company.Strong IP strategy can unlock funding, partnerships, and market exclusivity.Weak or mistimed IP decisions can permanently limit global opportunity.For founders and scientists: timing, geography, and disclosure discipline matter more than most people realize.About Our GuestDr. Kate NevillePartner, Marshall, Gerstein & BorunPhD in Immunology, JDLinkedIn: https://www.linkedin.com/in/kate-neville-phd/Firm Bio: https://www.marshallip.com/katherine-l-neville-ph-d/Charity Highlight: Girls on the Run ChicagoAn organization building confidence and resilience in young girls through mentorship and athletic achievement.https://www.girlsontherun.org/HostsDr. Chad BriscoeBioanalytical Scientific Leaderhttps://www.linkedin.com/in/chadbriscoe/Gregory AustinDirector, Business Development | Bioanalysishttps://www.linkedin.com/in/gregoryaustin1/If you enjoyed this episode, subscribe to BioTalk Unzipped on Apple Podcasts, Spotify, or your preferred platform and share with a colleague in biotech, pharma, or life sciences innovation.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we explore a series of significant shifts in the industry, marked by leadership changes, scientific advancements, strategic partnerships, and regulatory challenges.Starting with Sanofi, a notable leadership transition has taken place as Paul Hudson steps down from his role as CEO. Belen Garijo from Merck KGaA has stepped into this pivotal role. Her appointment is part of a broader industry trend toward diversifying leadership, especially with more women leading top-tier pharmaceutical companies. The implications of this shift could be profound for Sanofi, potentially stabilizing its operations and revitalizing its research pipeline. Stakeholders are keenly observing how this new leadership might steer Sanofi through complex market dynamics.In regulatory news, Moderna has encountered a significant hurdle with the FDA declining to review its next-generation mRNA flu vaccine. This decision has sparked an ongoing public dialogue between Moderna and U.S. health regulators, underscoring the complexities involved in navigating regulatory pathways for novel mRNA technologies beyond their initial success with COVID-19 vaccines. The Department of Health and Human Services has supported the FDA's decision, emphasizing the critical importance of meticulous scrutiny when it comes to new vaccine platforms. This development highlights the challenges biotech companies face in ensuring compliance with stringent regulatory standards.Financial updates reveal CSL experiencing a sharp decline in net profits, dropping from $2 billion to $384 million year-over-year. This financial downturn has been linked to strategic missteps or operational inefficiencies within the company, prompting a change in leadership. Such shifts reflect broader challenges faced by companies within the biotech sector as they strive to maintain financial stability amid fluctuating market conditions.In contrast, Alnylam Pharmaceuticals has reported its first profitable year despite underwhelming sales figures for its drug Amvuttra in the ATTR-CM market. This milestone is significant for Alnylam as it demonstrates resilience and the potential to pivot successfully amidst market uncertainties. However, the company will need to remain vigilant about revenue streams and market dynamics moving forward.Turning to advertising strategies, Johnson & Johnson's Tremfya continues to buck industry trends by maintaining a strong presence in television advertising through 2026. This strategy is noteworthy given the general decline in traditional media spending across the industry. J&J's commitment highlights its determination to sustain market share against competitors such as AbbVie's Rinvoq and Skyrizi.On the strategic front, Takeda Pharmaceuticals is consolidating its U.S. operations by reducing its Boston presence. By subleasing over 630,000 square feet of office space, Takeda aims to streamline operations and concentrate resources on key development projects at its new Cambridge hub. This move reflects broader industry trends towards operational efficiency and resource optimization.In clinical advancements, BridgeBio has reached a promising milestone with successful Phase 3 trial results for infigratinib in treating dwarfism. This breakthrough offers new therapeutic options for children affected by this condition and exemplifies ongoing innovations in genetic medicine. The success of this trial positions BridgeBio on a path toward regulatory approval, potentially transforming care for patients with limited treatment options.Agilent has achieved FDA approval for its companion diagnostic test alongside Merck's Keytruda for ovarian cancer treatment. This approval highlights the growing importance of precision medicine in oncology, where tailored treatments based on individual paSupport the show

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of transformative events shaping the landscape of drug development, regulatory scrutiny, and corporate strategies.At the forefront is Madrigal Pharmaceuticals' strategic acquisition of Ribo Therapeutics' preclinical siRNA programs, valued at $4.4 billion. This move aims to fortify Madrigal's liver disease drug portfolio alongside its promising candidate, resmetirom. By expanding into RNA-based therapies, Madrigal highlights an industry trend focused on gene silencing techniques to target genetic diseases more precisely.Turning to Moderna, it faces a regulatory hurdle as the FDA issued a refusal-to-file letter for its mRNA-based flu vaccine. The regulator's concerns about the trial design, specifically the use of a licensed standard-dose seasonal influenza vaccine as a control arm, emphasize the complexities of advancing mRNA technologies beyond COVID-19 applications. This situation underscores the necessity for meticulous trial designs that align with evolving regulatory standards.In cell therapy, allogeneic CAR-T treatments are gaining attention as companies strive to make these therapies more accessible by using T cells from healthy donors, rather than modifying a patient's cells. Despite technical challenges like graft-versus-host disease and immune rejection, these treatments promise streamlined manufacturing and reduced costs, marking a significant evolution from the pioneering autologous CAR-T success with Emily Whitehead in 2012. Eli Lilly's entry into CAR T-cell therapy through a $2.4 billion acquisition of Orna represents an ambitious expansion into autoimmune therapies. This strategic move exemplifies a broader trend where companies diversify portfolios to include emerging therapeutic modalities promising transformative impacts on patient care.In respiratory medicine, Upstream Bio's phase 2 trial of its TSLP receptor agonist showed encouraging results in reducing asthma exacerbations, comparable to Tezspire. However, falling short of best-case scenarios leaves room for competitors to present more compelling data. This illustrates the competitive nature of asthma treatment development and the ongoing quest for superior therapeutic options.A critical regulatory update arises from the NIH's decision to halt the Xarelto arm of a stroke prevention trial due to safety concerns. This decision highlights the indispensable role of independent monitoring committees in ensuring patient safety and meaningful clinical trial outcomes.On the corporate front, AstraZeneca has articulated an ambitious goal to achieve over 25 blockbuster drugs by 2030 as part of its strategy to reach $80 billion in revenue. This vision underscores the importance of innovation and strategic planning in sustaining growth within an increasingly competitive market.Fujifilm Biotechnologies' completion of its £400 million expansion project in the UK is another notable development, signaling robust investment in antibody production capabilities. This expansion positions Fujifilm as a key player in biopharmaceutical contract manufacturing and underscores the growing demand for flexible production technologies.The biotech sector is also witnessing significant activity with Pelage making strides in addressing hair loss through promising candidate developments. The market's enthusiasm for innovative solutions beyond traditional treatments reflects a broader demand for cutting-edge approaches to longstanding medical challenges.In obesity treatment, Novo Nordisk and Eli Lilly continue to lead with notable advancements. Novo Nordisk's recent developments with its Wegovy pill have been positively received, yet analysts question if this will suffice in maintaining their competitive edge given the dynamic nature of this therapeutic areSupport the show

In this episode of the Vital Health Podcast, host Duane Schulthess speaks with Tim Scott, President & CEO of Biocom California, a biopharma executive with more than two decades of experience, including spinning out companies from UC San Diego and leading firms acquired by BioMarin and Novartis, to discuss how California’s life sciences ecosystem became a global innovation engine, why the state’s research and venture networks matter, and how policy headwinds such as the Inflation Reduction Act (IRA) and Most Favored Nation (MFN) reference pricing reshape investment, rare disease development, and competition with Europe and China. Key Topics: Biocom Origins: Municipal policy roots, industry advocacy, ecosystem evolution across California. Innovation Network: University and research density, regional clusters, talent, and collaboration effects. Capital Pathway: NIH and NSF support, SBIR and STTR bridges, venture appetite, and liquidity. MFN and IRA: Pill penalty incentives, orphan exemption stakes, Medicare exposure, and VC pullback. Next-Gen Development: AI-enabled discovery, faster trial enrollment, digital twins, and regulator openness. Opinions expressed are those of the speakers.See omnystudio.com/listener for privacy information.

AZ TRT 2.0 - Solving the Worlds Problems through Design w/ Celeste Wilson of Form180 - AZ TRT S07 EP02 (285) 2-8-2026       Things We Learned This Week ·         People Are Remodeling Instead of Moving With rising home and land prices, homeowners are choosing to invest in their current homes—upgrading, expanding, and modernizing rather than starting over somewhere new. ·         Home Offices Are Now Permanent—and Must Be Designed Intentionally The best home offices allow for mental separation from work, often through physical barriers, visual breaks, or designing the space to flex back into daily living when the workday ends. ·         Wellness Is Driving Modern Home Design From smart lighting and steam showers to home gyms and better airflow, wellness is no longer a "nice to have"—it's a core design principle. ·         Lighting Directly Affects How a Home Feels Natural light, smart lighting systems, skylights, and color temperature all impact mood, energy, and subconscious comfort. Good lighting can completely transform older homes. ·         Great Design Starts With How People Actually Live Understanding family habits, entertaining style, pets, physical needs, and daily routines allows designers to create homes that feel peaceful, functional, and truly lived-in—not just beautiful.   Guest: Celeste Wilson - Founder | Principal Designer  FORM180.com           FORM180 is a full-service boutique architectural interior design firm located in sunny Arizona. Striking the balance between meticulous detail and welcoming allure, every project is a curation of precision and unparalleled craftsmanship. From initial concept to completion, we specialize in transforming spaces into experiences. Designing interiors that tell a story, empowering the minds that reside there. Our passion lies in crafting interiors that are not only stunning but deeply reflective of our clients' unique tastes and aspirations. Every detail, every finish, every handpicked piece is chosen to elevate and inspire.       Notes: In this episode, we sit down with Celeste Wilson of Form 180 Design, a residential-focused architecture and interior design firm known for modern, desert contemporary remodels. We explore why homeowners are choosing to remodel instead of move, how wellness and technology are shaping today's homes, and how Celeste's background in commercial design informs her approach to transforming older residential spaces. Segment 1: Why Home Remodeling Is Booming Why people are staying put ·         Rising housing and land prices have slowed moving activity ·         Homeowners are choosing to invest in and enjoy their current homes and neighborhoods ·         Remodels and additions are often more cost-effective than buying new Reimagining older homes ·         Common projects include ranch-style homes being reframed from dated layouts into clean, modern designs ·         Focus on transforming older homes without losing their character Post-COVID lifestyle shifts ·         Home offices are now a permanent feature ·         Demand for flexible workspaces that can transition back into living space ·         Importance of separating work energy from home life o    Physical or visual barriers o    Thoughtful placement and flow Wellness-driven design ·         Growing interest in: o    Home gyms o    Steam showers o    Wellness-focused layouts ·         Use of smart lighting and technology to enhance mood, circadian rhythm, and comfort ADUs & additions ·         Auxiliary Dwelling Units (ADUs) as: o    Detached home offices o    Guest houses or mother-in-law suites ·         Design considerations for privacy, access, and energy separation Kitchen remodel trends ·         Creating efficient kitchen work zones ·         Dedicated baking areas and improved storage ·         Butler's pantries to keep messes hidden and entertaining seamless Form 180 Design focus ·         Residential design first ·         Spec design, architectural design, and full-service interior design ·         Integrating technology with design to support wellness and livability Segment 2: Celeste Wilson's Design Philosophy & Background Professional background ·         Architectural design blended with interior design ·         10 years in commercial design, including: o    Abercrombie & Fitch (retail store layouts) o    Restaurants such as The Melting Pot, Sushi Go, and North & Company ·         15 years focused on luxury residential design Client-first design process ·         Starts with understanding the client's: o    Family structure o    Daily habits and lifestyle o    Physical needs or limitations o    Pets (feeding stations, pet zones, practical layouts) Designing for flow and peace ·         Every item should have a place ·         Homes should allow easy movement and freedom ·         Design supports how families live, cook, entertain, and relax ·         Goal: a symbiotic relationship between people and space Lessons from commercial design ·         Experience retrofitting modern layouts into historic buildings ·         Applying those lessons to older homes: o    Working within constraints o    Preserving character while modernizing function Upgrading older homes ·         Common challenges: o    Lower ceilings o    Smaller rooms ·         Solutions include: o    Lighter paint tones o    Strategic lighting o    Monochromatic palettes o    Vaulted ceilings (when budget allows) Lighting as a design tool ·         Door systems to open walls and increase natural light ·         Smart lighting systems (e.g., Lutron) o    Match interior lighting to natural UV patterns o    Light impacts mood and subconscious behavior ·         Skylights, larger windows, and creative daylight solutions ·         Even recreating sunlight through advanced lighting systems Floor plans & privacy ·         Creating intentional separation within intimate spaces ·         Split floor plans for primary bedrooms ·         Secondary entrances for: o    Home offices o    Guest suites o    Mother-in-law units Key Takeaway Great design isn't just about aesthetics—it's about how a space supports your life. From wellness and workflow to lighting and layout, Celeste Wilson's approach blends architecture, interior design, and human behavior to create homes that feel peaceful, functional, and timeless.     'Best Of' Topic: https://brt-show.libsyn.com/category/Best+of+BRT   Real Estate Topic: https://brt-show.libsyn.com/category/Real+Estate-Construction-Land-Farming        Thanks for Listening. Please Subscribe to the AZ TRT Podcast.     AZ Tech Roundtable 2.0 with Matt Battaglia The show where Entrepreneurs, Top Executives, Founders, and Investors come to share insights about the future of business.  AZ TRT 2.0 looks at the new trends in business, & how classic industries are evolving.  Common Topics Discussed: Startups, Founders, Funds & Venture Capital, Business, Entrepreneurship, Biotech, Blockchain / Crypto, Executive Comp, Investing, Stocks, Real Estate + Alternative Investments, and more…    AZ TRT Podcast Home Page: http://aztrtshow.com/ 'Best Of' AZ TRT Podcast: Click Here Podcast on Google: Click Here Podcast on Spotify: Click Here                    More Info: https://www.economicknight.com/azpodcast/ KFNX Info: https://1100kfnx.com/weekend-featured-shows/     Disclaimer: The views and opinions expressed in this program are those of the Hosts, Guests and Speakers, and do not necessarily reflect the views or positions of any entities they represent (or affiliates, members, managers, employees or partners), or any Station, Podcast Platform, Website or Social Media that this show may air on. All information provided is for educational and entertainment purposes. Nothing said on this program should be considered advice or recommendations in: business, legal, real estate, crypto, tax accounting, investment, etc. Always seek the advice of a professional in all business ventures, including but not limited to: investments, tax, loans, legal, accounting, real estate, crypto, contracts, sales, marketing, other business arrangements, etc.

The 2026 IPO Quiz: Since January 1, 2026How many companies?20How many total founders?34How many female founders?2: Cassandra Curtis and Jennifer GarnerHow many companies have female founders?1: Once Upon a FarmHow many companies with only female founders?0Once Upon a Farm: J. Garner, J. Foraker, C. Curtis, A. RazCo-founded in 2015 by Cassandra Curtis and Ari RazIn 2017, Jennifer Garner joined as a co-founder and “Chief Brand Officer”, alongside CEO John ForakerMost represented industry?Healthcare (5), including Pharma, Biotech, and AI Biotech How many are already down from their offer price (as of 10:45am)?17How many female chairs?1: Shoushana Ohanessian: VenHub GlobalHow many female CFOs?1: Cantor Equity VI: Jane Novak (F)How many female CEOsZeroHow many directly associated with Epstein Island?1: Cantor Equity VI: Cantor was founded over 75 years ago and was led by Howard W. Lutnick from 1992 until February 2025 when he became the United States Secretary of CommerceSon Brandon G. Lutnick CEO/ChairTrump Commerce Sec. Lutnick admits visiting Epstein island during family vacationHow many boards have ZERO male directors?ZEROHow many boards of zero female directors?Only six!How many with one? Only six!How many boards with at least 30% women? 4AgomAb Therapeutics 2/6 33%Green Circle Tech 2/5 40%Once Upon a Farm 4/9 44% (CEO/Chair, CFO, Nominating Committee chair, Compensation Committee chair = MEN)VenHub GlobalTotal percentage of women?18%BONUS HEADLINES QUIZKraft Heinz pauses work to split the company as new CEO says ‘challenges are fixable'What were the two new companies?Strategic Flavor Holdings Co. and North Atlantic Provisions Co.Global Taste Elevation Co. and North American Grocery Co.North Atlantic Snack Holdings and Strategic Grocery Development GroupInternational Flavor Solutions Co. and United Continental Grocery Co.Universal Taste Logistics Co. and North American Food Alignment Co.Proxy Voting: Asset Managers Increased Their Support for Management in 2025What percentage of management resolutions did the Big Three index managers support in the 2025 proxy year? Hint, it's up 3% since 2023.99% (98.7%), up from 96% in 2023Top 10 U.S. asset managers in 2025? 98%Top 50 U.S. asset managers in 2025? 96%What percentage of shareholder resolutions did the Big Three index managers support in the 2025 proxy year? Hint, it's down 1.5%.7.5%True or False: in a landmark social media case that seeks to hold tech companies responsible for harms to children, A google lawyer said this to Jurors yesterday: “It's not social media addiction when it's not social media and it's not an addiction.”True or False: xAI cofounder Jimmy Ba, the second cofounder [Tony Wu] to depart xAI in less than 48 hours, said this yesterday: "It's time to recalibrate my gradient on the big picture. 2026 is gonna be insane and likely the busiest (and most consequential) year for the future of our species."According to a new report from the WSJ, why did OpenAI fire Executive Ryan Beiermeister?sexual discriminationWhat's the story behind the story?Ryan Beiermeister, one of OpenAI's top safety executives, a vice president leading OpenAI's product policy team, was accused of sexual discrimination against a male employee after she voiced opposition to the controversial rollout of AI erotica in its ChatGPT product saying that she opposed adult mode, worried it would have harmful effects for users, and that she believed OpenAI's mechanisms to stop child-exploitation content weren't effective enough, and that the company couldn't sufficiently wall off adult content from teens.Beiermeister started a peer-mentorship program for women at OpenAI in early 2025.

In this episode of Data in Biotech, host Ross Katz sits down with James Yoder, Founder and CEO of OpenBench, to unpack a radical new approach to early-stage drug discovery. James shares how OpenBench's "success-driven" model shifts risk away from biotech partners by only charging for validated hits. They dive deep into computational screening, molecular modeling, and the company's evolving tech stack that's making hit discovery smarter and more accessible. Discover how data, AI, and strategic collaboration are redefining biotech R&D. What you'll learn in this episode: >> Why OpenBench moved away from SaaS to a success-based service model >> How their computational platform predicts binding affinity and screens trillions of compounds >> The role of data flywheels and ML in improving drug discovery success rates >> Real-world case studies from biotech collaborations >> How OpenBench evaluates druggable targets in one week Meet our guest James Yoder is the Founder and CEO of OpenBench. With a background in statistics, data science, and applied machine learning, he leads OpenBench's mission to deliver validated drug discovery hits through computational innovation and a success-driven business model. About the host Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with our guest: Sponsor: CorrDyn, a data consultancyConnect with James Yoder on LinkedIn  Connect with us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode!Connect with Ross Katz on LinkedIn Sponsored by… This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. In today's episode, we delve into the dynamic landscape of these industries, exploring ambitious strategic plans, regulatory hurdles, scientific breakthroughs, and emerging trends that are shaping the future of healthcare.Let's begin with AstraZeneca, which has set an ambitious target to achieve $80 billion in revenue by 2030. This goal reflects their intention to bring over 25 blockbuster drugs to market, underscoring a commitment to innovation and expansion in their therapeutic portfolio. The focus on cutting-edge research is not just a strategy for growth but also a sign of the broader industry trend where large pharmaceutical companies pursue high-value targets to strengthen their market positions. AstraZeneca is also making strides in the weight-loss market with its new candidate elecoglipron, undergoing an extensive late-stage program to evaluate its efficacy as a monotherapy and in combination treatments for various indications. This development positions AstraZeneca competitively in the burgeoning sector, offering a novel therapeutic option for obesity management.Meanwhile, CSL Limited is undergoing a leadership transition. CEO Paul McKenzie has stepped down under pressure, and Gordon Naylor has been appointed as interim chief. This change highlights the critical role of strategic leadership in navigating industry challenges and maintaining growth trajectories amidst a rapidly shifting market landscape.In a display of financial success, Novartis reported a record-breaking performance for 2025. This achievement led to a 30% increase in CEO Vas Narasimhan's compensation, reaching $32 million. The company's robust financial health is attributed to advancing innovative treatments targeting unmet medical needs, emphasizing how achieving innovation milestones can significantly enhance corporate valuation and leadership rewards.Incyte is preparing for the patent expiration of its blood cancer drug Jakafi in 2028 by focusing on Opzelura, a topical cream that has witnessed a 33% sales increase from the previous year. With sales reaching $678 million, Opzelura's success highlights Incyte's strategic pivot to diversify its product offerings and mitigate risks associated with patent cliffs. This exemplifies how companies must continuously innovate and adapt to maintain competitive advantages.Moderna has entered into a long-term agreement with Mexico to ensure local mRNA vaccine supply through technology transfer to Laboratorios Liomont. This partnership extends Moderna's global footprint and underscores the critical role of mRNA technology in pandemic preparedness and vaccine accessibility, reinforcing its transformative impact on public health strategies.Regulatory landscapes have also seen notable activity. The FDA issued untitled letters concerning potentially misleading drug advertisements from companies like Novo Nordisk, Argenx, and Sobi. Such actions emphasize regulatory vigilance in marketing practices. Additionally, Lilly's Kinsunla failed to secure approval in Scotland, while Regenxbio faced rejection for its gene therapy for Hunter syndrome. These regulatory hurdles highlight the rigorous oversight pharma companies face and the complex pathways drugs must navigate before market approval.Collaborations within the industry are proving crucial for innovation. Merck's collaboration with Calla Lily Clinical Care aims to enhance delivery systems for vaginal therapeutics. Similarly, Bristol Myers Squibb's partnership with Evinova focuses on integrating AI into clinical development processes. These alliances reflect an industry-wide emphasis on leveraging technology to improve drug delivery efficiency and streamline clinical trial operations.Shifting our focus now to scientific advancements and clinical trial results that aSupport the show

What if helping the immune system find balance could meaningfully slow disease progression for diseases like ALS or Alzheimer's? In this episode of Rx for Biotech, host Chris Leidli sits down with Arun Swaminathan, CEO of Coya Therapeutics, to talk about a new and hopeful approach to treating neurodegenerative diseases by calming harmful inflammation in the body. This conversation offers a hopeful look at how science is working to improve quality of life for patients and families facing neurodegenerative disease. Arun also shares insights from his 20+ years in biotech leadership, including what it takes to advance novel immunology science in high-unmet-need indications and build a product pipeline across neurodegenerative, autoimmune, and inflammatory diseases.

Live Feb 10, 2026 | Yaron Brook ShowSeason 12, Episode 26Bridge to?; TrumpRx; Climate Regs; Internet addiction; Discord; SpaceX; Russia | Yaron Brook ShowIs America Building a Bridge to Greatness… or to Decline? From TrumpRx to Climate Controls, SpaceX to Russia — Nothing Is Off Limits.Is America building a bridge to the future — or a bridge to nowhere?In this explosive episode of The Yaron Brook Show, Yaron takes on everything from Trump's policy prescriptions (“TrumpRx”) to climate regulations, internet addiction, Discord culture, SpaceX's ambitions, and Russia's geopolitical threat.No topic is safe. No sacred cows spared.If you care about capitalism, individual rights, Elon Musk, government overreach, the FDA, Putin, or the future of freedom — this episode delivers clarity you won't hear anywhere else.

Matt Hampton and Dr Tom Ingegno came into my world the way the best guests always do. They found me first. They pulled me onto their Irreverent Health Podcast, a show that blends medicine, curiosity, and unapologetic nonsense the same way Gen X kids blended Saturday morning cartoons with nuclear-war anxiety. We recorded together, we went off the rails together, and by the end I told them the rule. If you ever come to New York, you sit in my studio. No exceptions.They showed up. They took the hot seat. They told Alexa to shut up. They joked about Postmates. They compared bifocals before I even hit record. From there it turned into a full blown eighties time machine powered by weed policy, AI diagnostics, acupuncture philosophy, art school trauma, cannabis data science, paranormal detours, and the kind of deep cut pop culture references only Gen X survivors can decode.Matt builds AI systems. Tom heals people with needles and a lifetime of East Asian medicine. Together they make healthcare funny without pretending it works. They remind you that curiosity carries weight when the system collapses under its own stupidity.This episode is a reunion of three loudmouths raised on Atari, late night cable, and the hard lesson that you either tell the truth or get flattened by it. Go subscribe to Irreverent Health. These guys earned it.RELATED LINKS• Irreverent Health Podcast• Matt Hampton – Consilium Institute• Envoy Design• Dr. Tom Ingegno – Charm City Integrative Health• The Cupping Book• You Got Sick—Now What?• Matt Hampton on LinkedIn• Dr. Tom Ingegno on LinkedInFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Synopsis: At JPM 2026 in San Francisco, Alok Tayi welcomes Michelle Werner, CEO of Alltrna, to Biotech 2050 for a powerful conversation at the intersection of personal mission, platform biology, and rare-disease drug development. Michelle traces her two-decade career across Bristol Myers Squibb, AstraZeneca, and Novartis—and the moment everything changed when her child was diagnosed with a rare disease. That experience led her to Alltrna and its pioneering engineered tRNA platform, designed to correct nonsense mutations across hundreds—potentially thousands—of genetic disorders with a single therapeutic approach. Together, Alok and Michelle explore how tRNAs work, why “stop-codon disease” could redefine rare-disease classification, and how basket trials borrowed from oncology may accelerate development. They dive into delivery strategy, portfolio expansion into CNS and muscle disorders, regulatory innovation, and how AI is reshaping molecular design—offering a rare look at what it takes to build a first-in-class modality from the ground up. Biography: Michelle is a seasoned pharmaceutical executive with more than 20 years in the industry spanning commercial and research & development (R&D) responsibilities. Prior to Alltrna, Michelle served as Worldwide Franchise Head, Solid Tumors at Novartis Oncology, where she was responsible for delivering the disease area strategies across multiple tumors and led business development efforts resulting in a doubling of long-term portfolio value for the franchise. Previous to Novartis, Michelle was a senior leader at AstraZeneca and as Global Franchise Head in Hematology, she was critical in launching multiple indications worldwide for CALQUENCE®. Prior to this, Michelle was Head of US Oncology, where she led the business through dramatic growth in both team and revenue through eight-plus product launches. Previous to AstraZeneca, Michelle was with Bristol-Myers Squibb for 10 years in various positions of increasing responsibility including roles in sales, marketing, and market access in the US and UK, and above market in Europe (based in France) and global almost exclusively in oncology. Michelle started her professional career in R&D, working hands-on with patients at the Oncology Clinical Trials Unit at Harvard Medical School before moving into industry in clinical operations. Outside of her corporate responsibilities, Michelle is a wife and mother to three children and is a member of the rare disease community. She is currently serving a Board appointment for the non-profit organization Rare Disease Renegades, a purpose that fuels her passions both personally and professionally.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a range of stories that highlight the dynamic and often challenging landscape of these industries, as they navigate through scientific breakthroughs, strategic collaborations, regulatory hurdles, and market trends.Starting with corporate restructuring, Roche's Genentech has announced significant layoffs, totaling 489 positions in the previous year. This move is part of broader restructuring efforts seen across large pharmaceutical companies like Bayer and Bristol Myers Squibb. The layoffs illustrate the tightening financial and scientific constraints that are influencing pipeline decisions and capital allocation. Companies are facing increasing pressures to maintain credibility while also dealing with economic challenges that impact their strategic directions.On the regulatory front, the U.S. Department of Health and Human Services (HHS) encountered legal setbacks concerning its 340B rebate model pilot program. Following a lawsuit from the American Hospital Association, HHS withdrew notices and application approvals for this initiative. This development indicates a need for more comprehensive public feedback before any future attempts at similar programs are made, highlighting how complex regulatory landscapes can become.Turning to clinical trials, Fierce Biotech identified several significant failures in 2025, underscoring the inherent risks involved in drug development. These setbacks emphasize the importance of robust trial designs and execution strategies to mitigate risks. Meanwhile, Fresenius Kabi and Phlow Corporation have announced a strategic alliance to produce epinephrine injection API in the U.S., aiming to strengthen supply chain resilience—a crucial lesson learned from vulnerabilities exposed during the COVID-19 pandemic.Eli Lilly has made waves with its $2.4 billion acquisition of Orna Therapeutics, marking its entry into the in vivo CAR-T space. This acquisition underscores a growing interest in advanced cell therapies with transformative potential for cancer treatment. Additionally, Lilly has expanded its collaboration with Innovent Biologics through a $350 million upfront payment and milestone payments totaling $8.8 billion, focusing on oncology and immunology. This reflects a shift towards deeper integration in drug development efforts beyond traditional licensing models.Takeda Pharmaceuticals' $1.7 billion AI-driven drug discovery agreement with Iambic Therapeutics highlights the increasing adoption of artificial intelligence to accelerate drug discovery processes. AI's potential to enhance precision medicine approaches is becoming more pronounced as companies seek innovative methods to improve target identification and lead optimization.In market dynamics, Hims & Hers withdrew from launching a generic version of Novo Nordisk's weight loss pill due to regulatory pressures from the FDA. This incident underscores the complex interplay between innovation and compliance that companies must navigate when bringing new therapeutics to market. Additionally, legal actions have been initiated by Novo Nordisk against Hims & Hers over patent infringement claims related to semaglutide—a case highlighting ongoing challenges in patent protection within rapidly evolving drug compounding arenas.Eli Lilly also leveraged the global stage of the Winter Olympics for a campaign drawing parallels between scientific progress and athletic achievement. Such campaigns align with industry efforts to enhance public perception and trust amid ongoing challenges.Overall, while the pharmaceutical and biotech industries face significant challenges—from regulatory hurdles to clinical trial setbacks—there are substantial opportunities for growth driven by technological advancements and strategic collaborations. NaSupport the show

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, we're speaking with Cindy Perettie, Executive Vice President and Global Head at Kite Pharma, a Gilead-owned company focused on curing cancer with cell therapies. Perettie talks about scaling cell therapies in the community setting, global manufacturing strategy, preparing for the launch of late-stage development programs in lymphoma and multiple myeloma, and working with partners like Arcellx. She also discusses cell therapy funding cycles and big pharma, the autologous versus allogeneic divide, why in vivo CAR-T therapies could be a game changer, what the FDA's focus on cell and gene therapies could mean for U.S. competition, and more. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

Today's returning guests are Dan Rasmussen, founder of Verdad Advisers, and D.A. Wallach, a venture capital investor for Time BioVentures. In today's episode, we unpack the recent biotech surge through the lens of Dan's recently published biotech report. We also explore China's growing biotech market, shifting IPO and VC trends, and how valuation tools like CAPE fit into today's regime. Finally, we also discuss technology's effect on productivity and corporate profits in the US, Japan's economic anomaly, home country bias, and more. (0:00) Starts (1:20) Dan's research on the biotech sector (19:10) D.A. on biotech in China (27:01) IPO landscape (31:01) Biotech VC update from D.A. (32:16) Are US stocks overvalued? (51:53) Dan's view of Japanese stocks (57:40) Global equity markets and home country bias (1:03:34) Book recommendations (1:11:55) Wrap-up and future plans ----- Follow Meb on X, LinkedIn and YouTube For detailed show notes, click here To learn more about our funds and follow us, subscribe to our mailing list or visit us at cambriainvestments.com ----- ⁠ ----- Sponsor: Visit ⁠⁠Alpha Architect's 351 Education Center⁠⁠ for use cases, tools, FAQs, upcoming launches, and more. Follow The Idea Farm: X | LinkedIn | Instagram | TikTok ----- Interested in sponsoring the show? Email us at Feedback@TheMebFaberShow.com ----- Past guests include Ed Thorp, Richard Thaler, Jeremy Grantham, Joel Greenblatt, Campbell Harvey, Ivy Zelman, Kathryn Kaminski, Jason Calacanis, Whitney Baker, Aswath Damodaran, Howard Marks, Tom Barton, and many more.  ----- Meb's invested in some awesome startups that have passed along discounts to our listeners. Check them out here!  ----- Editing and post-production work for this episode was provided by The Podcast Consultant (https://thepodcastconsultant.com). Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode of The Steward Chair, Maria Thacker Goethe, President and CEO of Georgia Life Sciences, shares her journey of transitioning from a dedicated "number two" to leading a massive ecosystem through a global pandemic. We explore how a commitment to mission and the guidance of mentors drives meaningful, long-term success even when the original plan is upended. We discuss the critical role of a connector in the life sciences sector, the importance of "work-life harmony" over balance, and why true stewardship means preparing the next generation to lead. This conversation provides actionable takeaways for leaders committed to stewardship, integrity, and impact. Key Takeaways Purpose Over Tactics: In times of crisis, your "North Star" must be your organizational purpose, allowing your tactics to remain nimble and adaptive. The Responsibility of Mentorship: Leadership is a societal responsibility; investing time in the next generation is essential because no leader is "here forever". Embracing "Ready Enough": You don’t have to feel fully ready to step into a leadership seat; surrounding yourself with a community that believes in you is the key to moving forward through fear. Resources Mentioned Visit https://www.galifesciences.org/ Follow Maria on LinkedIn at https://www.linkedin.com/in/mariathacker/ Join the Georgia Life Sciences mailing list at: https://www.galifesciences.org/join-the-mailing-list Join the ConversationThe Steward Chair is about equipping and inspiring business leaders to build organizations that stand the test of time. If this episode resonated with you, share your biggest takeaway and tag us on LinkedIn @ChatWithLeaders. Elevate your podcast, company meeting, or industry event strategies to better engage stakeholders and drive meaningful growth! Visit ChatWithLeaders.com to learn more about how we can help.See omnystudio.com/listener for privacy information.

Bill Thach has had 9 lines of treatment, over 1,000 doses of chemo, and more scans than an airport. He runs ultramarathons for fun. He jokes about being his own Porta Potty. He became a father, then got cancer while his daughter was 5 months old. Today she is 8. He hides the worst of it so she can believe he stands strong, even when he knows that hiding has a cost.We talk about the illusion of strength, what it means to look fine when your body is falling apart, and how a random postcard in an MD Anderson waiting room led him to Man Up to Cancer, where he now leads Diversity and AYA Engagement. Fatherhood. Rage. Sex. Denial. Humor. Survival. All that and why the words good morning can act like a lifeline.RELATED LINKSFight Colorectal CancerCURE TodayINCA AllianceMan Up to CancerWeeViewsYouTubeLinkedInFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Big pharma and biotech take the earnings stage this week with reports from Eli Lilly (NYSE: LLNY) and Novo Nordisk (NYSE: NVO) leading the lineup. Will they help the industry once again outperform AI champ NVIDIA (NASDAQ: NVDA), as the industry did in 2025? Karl Thiel, Tom King, and Tim Beyers discuss: - Slow rolling chaos at FDA and its effects on drug approvals. - How to think about risk when investing in biotech. - Earnings predictions for Lilly and Novo as well as a review of results from DNA researcher Twist Bioscience (NASDAQ: TWST). Don't wait! Be sure to get to your local bookstore and pick up a copy of David's Gardner's new book — Rule Breaker Investing: How to Pick the Best Stocks of the Future and Build Lasting Wealth. It's on shelves now; get it before it's gone! Companies discussed: RGNX, LLY, NVO, TWST Host: Tim Beyers Guests: Karl Thiel, Tom King Producer: Anand Chokkavelu Engineer: Dan Boyd Disclosure: Advertisements are sponsored content and provided for informational purposes only. The Motley Fool and its affiliates (collectively, “TMF”) do not endorse, recommend, or verify the accuracy or completeness of the statements made within advertisements. TMF is not involved in the offer, sale, or solicitation of any securities advertised herein and makes no representations regarding the suitability, or risks associated with any investment opportunity presented. Investors should conduct their own due diligence and consult with legal, tax, and financial advisors before making any investment decisions. TMF assumes no responsibility for any losses or damages arising from this advertisement. We're committed to transparency: All personal opinions in advertisements from Fools are their own. The product advertised in this episode was loaned to TMF and was returned after a test period or the product advertised in this episode was purchased by TMF. Advertiser has paid for the sponsorship of this episode. Learn more about your ad choices. Visit ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠megaphone.fm/adchoices Learn more about your ad choices. Visit megaphone.fm/adchoices

The Nurses Report with David, Nicole & Ashley – Nurses examine the expanding intersection of biotech and Big Tech, raising urgent questions about health data, surveillance, and human dignity. As biologics, wearables, and corporate power converge, the conversation challenges listeners to consider consent, autonomy, and the spiritual cost of unchecked innovation in modern healthcare...